Icad Inc Stock Price, News & Analysis

iCAD, Inc. (NASDAQ: ICAD) will announce its second-quarter financial results on August 10, 2022, after market closure. The results will be followed by a conference call at 4:30 PM ET. This announcement highlights iCAD's ongoing commitment to transparency and investor engagement as it continues to provide innovative solutions in cancer detection and therapy.

iCAD, Inc. (NASDAQ: ICAD) showcased its Breast AI solutions at the European Congress of Radiology, including ProFound AI Risk, which has demonstrated the ability to identify high-risk women with a 32 times greater risk of breast cancer. Clinically proven, this AI tool is 2.4 times more accurate than traditional models, offering a unique approach by using mammographic features for short-term risk estimation. The innovations aim to enhance clinical practice by reducing unnecessary patient recalls, thereby improving breast cancer screening outcomes.

iCAD, a leader in cancer detection, is hosting a webinar on July 18, 2022, titled “ProFound AI Risk in the Real-World”. Esteemed radiologists will showcase clinical examples using iCAD’s ProFound AI Breast Health Solutions to illustrate its effectiveness in personalizing breast cancer screening. The event will feature experts like Mark Traill and Axel Gräwingholt, sharing insights from real-world cases. This follows a prior webinar that discussed the technology's impact on cancer detection rates and efficiency.

iCAD, a leader in cancer detection technology, is set to host a webinar titled “Risk Assessment Reimagined” on June 21, 2022. This event will feature expert discussions, including researchers from Karolinska Institutet, on the effectiveness of ProFound AI® Risk for Digital Breast Tomosynthesis (DBT). This innovative tool provides personalized short-term breast cancer risk assessments based solely on mammogram data, demonstrating up to 2.4 times more accuracy than traditional models. The webinar will further explore its implications for improving patient outcomes and screening compliance.

iCAD, a leader in cancer detection technology, will participate in the JMP Securities Life Sciences Conference on June 15-16, 2022, in New York City. CEO Stacey Stevens is scheduled to present on June 15 at 9:00 a.m. EDT. Interested parties can access the webcast here. iCAD specializes in innovative solutions for cancer diagnosis and therapy, aiming to improve patient care through advanced technologies.

iCAD, Inc. (NASDAQ: ICAD) has appointed Stephen P. Sarno as the interim Chief Financial Officer, effective immediately. Sarno's previous experience includes CFO roles in various technology organizations. He takes over from Charles Carter, who is departing the company this month. Sarno expressed excitement about joining iCAD during a pivotal growth phase, emphasizing the firm's innovative technologies in cancer detection and therapy. iCAD aims to enhance operational efficiency and patient outcomes as it continues its strategic vision for increased shareholder value.

Research at the 2022 SBI/ACR Breast Imaging Symposium has confirmed that ProFound AI significantly improves radiologists’ screening performance in breast cancer detection using Digital Breast Tomosynthesis (DBT). The study showed enhancements in cancer detection rates and reduced false positives. ProFound AI, recognized as the first FDA-cleared AI cancer detection software for DBT, boosts reading speed by 52.7% and improves sensitivity by 8%. iCAD showcases its complete AI solutions at the symposium, indicating strong potential for transforming breast cancer screening.

iCAD has announced positive results from clinical research supporting its ProFound AI Risk tool for Digital Breast Tomosynthesis (DBT), indicating that 14% of women with a negative screen had a significantly elevated risk of developing breast cancer. The study, involving over 154,200 women, achieved an area under the curve (AUC) of 0.82, underscoring its predictive accuracy compared to traditional models. This advancement aims to refine breast cancer screening strategies, potentially improving early detection and outcomes.

iCAD (NASDAQ:ICAD), a leader in medical technology, will present at the Spring Into Action - Best Ideas Virtual Investor Conference from May 16-20, 2022. Stacey Stevens, President and CEO, is scheduled to speak on May 17 from 11:30 to 11:55 a.m. EST. The presentation will be available for live webcast and replay. Investors interested in one-on-one meetings or further details can email angie.wright@issuerdirect.com. For registration, visit here.